Opinion|Videos|October 6, 2023
Evolving Practice Standards for ER+/HER2- Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD
A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5